Markets
ALL

Juno Therapeutics' (JUNO) Q4 Loss Wider than Expected - Analyst Blog

A generic image of a smart phone with a stock chart on it
Credit: Shutterstock photo

Juno Therapeutics Inc.JUNO reported a fourth-quarter 2014 adjusted loss (including non-cash stock-based compensation expense) of $1.73 per share, much wider than the Zacks Consensus Estimate of a loss of 33 cents. This was the company's first reported quarter.

The company did not generate any revenue in the quarter.

Juno Therapeutics' 2014 adjusted loss (including non-cash stock-based compensation expense) of $7.54 per share was also much wider than the Zacks Consensus Estimate of a loss of $1.82. 2014 revenues were likewise nil.

The company's adjusted research and development expenses came in at $14.5 million. Meanwhile, the company's general and administrative expenses were $6.4 million.

Pipeline Update

Juno Therapeutics has several candidates in its pipeline. The company's pipeline consists of a number of leukemia candidates including JCAR015 (acute lymphoblastic leukemia (ALL), phase I), JCAR017 (relapsed/refractory ALL, phase I/II), JCAR014 (chronic lymphocytic leukemia, non-Hodgkin's lymphoma (NHL) and ALL, phase I/II studies) and JCAR018 (ALL and NHL, phase I) among others.

The company is currently preparing to start a phase II study on JCAR015 in the ALL indication.

2015 Guidance

Juno Therapeutics expects a cash burn of $125 million and $150 million in 2015 excluding cash inflows or outflows from business development activities and other ongoing activities.

Our Take

The company's fourth-quarter results were disappointing, as it missed our estimates by a wide margin. Although the company has several candidates in its pipeline, all of them are in early stages of development and have to go a long way before hitting the market. Moreover, there are several companies like Roche RHHBY that are already marketing leukemia drugs.

We expect investor focus to stay on the company's pipeline and future results.

Juno Therapeutics carries a Zacks Rank #3 (Hold). Cytokinetics, Incorporated CYTK and Affymetrix Inc. AFFX are better-ranked stocks in the health care sector. Both stocks carry a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report

AFFYMETRIX INC (AFFX): Free Stock Analysis Report

CYTOKINETCS INC (CYTK): Free Stock Analysis Report

JUNO THERAPEUTC (JUNO): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ALL CYTK

Other Topics

Stocks

Latest Markets Videos